Imugene (IMU.AX)

Executive Summary

Imugene Limited (ASX: IMU) is an Australian clinical-stage immuno-oncology company developing novel cancer therapies, including oncolytic virotherapies (CF33 platform) and bispecific antibodies (PD1-Vaxx). The company's pipeline targets solid tumors and hematologic malignancies, with seven candidates in clinical trials. Recent progress includes the completion of a Phase 1 trial of CF33-hNIS combined with pembrolizumab and chemotherapy (NCT05346484) and the termination of a CF33-CD19 trial (NCT06063317). Key active trials include a Phase 1 oncolytic virus (CF33-expressing hNIS/anti-PD-L1) for metastatic triple-negative breast cancer (NCT05081492), which completed enrollment in March 2026 with data expected soon, and a Phase 1 CAR-T therapy (Azer-cel) for non-Hodgkin lymphoma (NCT03666000) recruiting through 2027. Despite setbacks in some programs, Imugene continues to advance its innovative platforms. The company's valuation remains modest (~A$44M), reflecting early-stage risk and potential upside from upcoming catalysts.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for CF33-hNIS oncolytic virus in metastatic triple-negative breast cancer (NCT05081492)60% success
• H2 2026Interim update from Phase 1 Azer-cel trial in non-Hodgkin lymphoma (NCT03666000)50% success
• TBDPotential partnership or financing deal to advance pipeline40% success